IBO: Impact BioMedical, Inc. EV/EBITDA Multiple
Impact BioMedical Inc (IBO) efficiency relies on the commercialization of medical patents and the successful transition of R&D projects to the sales stage. The quotes provided below with the 0.00 indicator confirm the current business valuation. However, the fragmentation of bio-assets and a high burn rate create financial challenges. Management is currently focusing on the protection of property rights and preclinical tests, anticipating revenue growth from licensing agreements.
Analytical breakdowns for Impact BioMedical Inc
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Impact BioMedical Inc|IBO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Impact BioMedical Inc|IBO - Company Total Debt|Debt to Book Capitalization Ratio Impact BioMedical Inc|IBO - Long-Term Liabilities|Company Short-Term Debts Impact BioMedical|Quick Ratio impactbiomedinc.com
- financial results and valuation multiples details:
IBO - Net Income|Future Profit Impact BioMedical Inc|IBO - Market Price to Net Income Ratio|Projected Price to Earnings Impact BioMedical|IBO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Impact BioMedical Inc|IBO - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Impact BioMedical|IBO - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months impactbiomedinc.com|IBO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Impact BioMedical Inc
Analysis of all company metrics:IBO (Impact BioMedical)
This ratio compares the total enterprise value, net of liquid assets, to its operating profit before taxes and depreciation. By analyzing the EV/EBITDA valuation multiple for capital-intensive businesses, the investor sees a current value of 0.00, reflecting the business value relative to the generated cash flow. For Impact BioMedical Inc (IBO), this metric is critical, as the automation gap—ranging from point bio-robots to rights management systems—directly impacts capital intensity and the growth rate of operational efficiency.
Direct competitors
Haleon Group - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KVUE (Kenvue Health)|Verona Pharma plc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation MENS (jyongbio.com)|LGND: EV/EBITDA Multiple|Company Value to EBITDA Amneal Pharmaceuticals, Inc. (AMRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Perrigo Company|ALVO: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LQDA|Total Company Value to Operating Income Before Depreciation Ratio glpg.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PCRX|SPRY: EV/EBITDA Multiple|theravance.com (TBPH) - EV/EBITDA Multiple|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio scPharma (SCPH)|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio TNXP|China SXT Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EPRX|BioHarvest Sciences Inc. - EV/EBITDA Multiple|EXOZ: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ORMP: EV/EBITDA Multiple|ENTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|Company Value to EBITDA abvcpharma.com ABVC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cumberland Pharmaceuticals Inc. (CPIX)|Enterprise Value to EBITDA Ratio Quantum BioPharma Ltd. QNTM|EV/EBITDA Multiple FGEN (FibroGen Corp)|Telomir Pharmaceuticals Corp (TELO) - Company Value to EBITDA|Rani Therapeutics Inc - EV/EBITDA Multiple|SNYR (Synergy CHC Corp) - Enterprise Value to Operating Income Before Depreciation|RLYB: EV/EBITDA Multiple|LEXX - Total Company Value to Operating Income Before Depreciation Ratio|PULM (Pulmatrix Corp) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pheton (PTHL)|EV/EBITDA Multiple APM|EV/EBITDA Multiple lyratherapeutics.com (LYRA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRFX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CYTO (Altamira Therapeutics)|LIPO: EV/EBITDA Multiple|OPTN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Enterprise Value to Operating Income Before Depreciation PROC (Procaps Group)|EV/EBITDA Multiple PTPI|Enterprise Value to EBITDA Ratio Qilian International Corp QLI|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio tffpharma.com (TFFP)
